BSTC: BioSpecifics Technologies Corp. - Summary | Jitta

BioSpecifics Technologies Corp.

NASDAQ:BSTC

Notice
Stock data is unavailable or the company’s delisted.
Price
$88.53
Loss Chance
47.5%
5.84JITTA SCORE
68.60%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (45)
Recent Business Performance (41)
Financial Strength (94)
Return to Shareholders (45)
Competitive Advantage (70)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 5 years
Recent Business PerformanceEarning Growth Last Year
Operating MarginExpansion
Debt LevelLow Long Term Debt
CapExVery Low
SG&A to SalesDecreasing
Key Stats
Jitta Score
Jitta Line
5.84
68.60%
2.20
144.61%
3.06
136.28%
Biotechnology
6.05
104.12%
5.66
27.67%
5.83
12.40%
COMPANY DESCRIPTION
BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware. As of December 1, 2020, BioSpecifics Technologies Corp. operates as a subsidiary of Endo International plc.